Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 7/20 | 0.44 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3502114 | 0.99 | BCHE (0.50) | BCHEACHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3502287 | 0.90 | HTR3A (0.50) | BCHEACHENPC1RAB9AAURKA | |
| SCHEMBL3502230 | 0.90 | TP53 (0.54) | BCHEACHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3502120 | 0.84 | AURKA (0.53) | BCHEACHENPC1RAB9ASMN1; SMN2 | |
| SCHEMBL3501399 | 0.80 | AURKA (0.42) | AURKATP53KDM4EALKBH3MAPT | |
| SCHEMBL3501780 | 0.78 | AURKA (0.46) | NPC1RAB9ASMN1; SMN2ALDH1A1PKM | |
| SCHEMBL1054586 | 0.77 | AURKA (0.53) | NPC1RAB9ASMN1; SMN2AURKATP53 | |
| SCHEMBL4305932 | 0.76 | AURKA (0.52) | NPC1RAB9ASMN1; SMN2AURKATP53 | |
| SCHEMBL3500007 | 0.74 | AURKA (0.43) | ALDH1A1AURKATP53KDM4EALKBH3 | |
| SCHEMBL1054292 | 0.73 | AURKA (0.64) | BCHEACHENPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-07-22 | — | — | US | disclosed |
| US-7598268-B2 | Quinolinone derivatives | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-03-20 | — | — | US | disclosed |
| US-7335774-B2 | Quinolinone derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | CHIRON CORPORATION | 2005-09-22 | — | — | US | disclosed |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | CHIRON CORPORATION | 2005-03-10 | — | — | US | disclosed |
| US-6800760-B2 | INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE | CHIRON CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6774237-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASES INHIBITORS; ANGIOGENESIS INHIBITORS, ANTICARCINOGENIC AGENTS | CHIRON CORPORATION | 2004-08-10 | — | — | US | disclosed |
| US-6762194-B2 | VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS | CHIRON CORPORATION | 2004-07-13 | — | — | US | disclosed |
| US-6605617-B2 | Treating a patient in need of an inhibitor of vascular endothelial growth factor receptor tyrosine kinase | CHIRON CORPORATION | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070906-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | BCHE 2329/4885ACHE 834/4885NPC1 214/4885 |
| US-20050054672-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor;angiogenesis inhibitor; anticarcinogenic agents | VEGFA, FLT1, KDR | BCHE 4441/4885ACHE 4438/4885NPC1 2332/4885 |
| US-20050209456-A1 | Vascular endothelial growth factor; tyrosine kinase inhibitor; angiogenesis inhibitor; anticancer agents | KDR, FLT4, FLT1 | BCHE 4635/4885ACHE 4670/4885NPC1 4748/4885 |
| US-20100184754-A1 | QUINOLINONE DERIVATIVES | SLCO1B1, SLCO1B3, SLCO1A2 | BCHE 2329/4885ACHE 834/4885NPC1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.